Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV

Cherry, Catherine L.; Affandi, Jacquita S.; Brew, Bruce J.; Creighton, Jason; Djauzi, Samsuridjal; Hooker, David J.; Imran, Darma; Kamarulzaman, Adeeba; Kamerman, Peter R.; McArthur, Justin C.; Moore, Richard D.; Price, Patricia; Smyth, K; Tan, Ik Lin; Vanar, Sasheela; Wadley, Antonia L.; Wesselingh, Steven Lodewyk; Yunihastuti, Evy

doi:10.1212/wnl.0b013e3181dd436d

Cited by 19 publications

(12 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In agreement with other studies, the risks of DSP and CNS OI were not higher in HIV-infected persons with HCV co-infection [25,42]. The similar prevalence of overall neurocognitive impairment between HIV-infected and HIV/HCV co-infected individuals was similar to the previous report by Ryan et al [16]; however, the prevalence of HIVassociated dementia in HIV/HCV co-infected individuals was not higher than HIV-infected individuals.…”

Section: Discussionsupporting

confidence: 92%

“…The greater prevalence and severity of fatigue and depression were also reported in individuals with HCV seropositivity [15,24]. In contrast, distal sensory polyneuropathy (DSP), the most common neurological disorder in HIV-infected persons, was not associated with HCV seropositivity and active HCV replication in HIV/ HCV co-infected persons [25,26]. However, the overall prevalence of different neurologic disorders in individuals with HIV and HCV coinfection remains uncertain.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS

Vivithanaporn

Nelles

DeBlock

et al. 2012

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS

Vivithanaporn

Nelles

DeBlock

et al. 2012

Journal of the Neurological Sciences

View full text Add to dashboard Cite

“…Hepatitis C is a frequent and serious coinfection of HIV patients, and the possibility that it influences neurological outcomes continues to be a concern. Our analyses support other observations about the lack of association of HCV coinfection with neuropathy [42]. …”

Section: Discussionsupporting

confidence: 91%

Peripheral neuropathy in HIV: prevalence and risk factors

Evans

Ellis

Chen

et al. 2011

Aids

178

171

View full text Add to dashboard Cite

Objectives To estimate neuropathic sign/symptom rates with initiation of combination antiretroviral therapy (cART) in HIV-infected ART-naive patients, and to investigate risk factors for: peripheral neuropathy and symptomatic peripheral neuropathy (SPN), recovery from peripheral neuropathy/SPN after neurotoxic ART (nART) discontinuation, and the absence of peripheral neuropathy/SPN while on nART. Design AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trial participants who initiated cART in randomized trials for ART-naive patients were annually screened for symptoms/signs of peripheral neuropathy. ART use and disease characteristics were collected longitudinally. Methods Peripheral neuropathy was defined as at least mild loss of vibration sensation in both great toes or absent/hypoactive ankle reflexes bilaterally. SPN was defined as peripheral neuropathy and bilateral symptoms. Generalized estimating equation logistic regression was used to estimate associations. Results Two thousand, one hundred and forty-one participants were followed from January 2000 to June 2007. Rates of peripheral neuropathy/SPN at 3 years were 32.1/8.6% despite 87.1% with HIV-1RNA 400 copies/ml or less and 70.3% with CD4 greater than 350 cells/µl. Associations with higher odds of peripheral neuropathy included older patient age and current nART use. Associations with higher odds of SPN included older patient age, nART use, and history of diabetes mellitus. Associations with lower odds of recovery after nART discontinuation included older patient age. Associations with higher odds of peripheral neuropathy while on nART included older patient age and current protease inhibitor use. Associations with higher odds of SPN while on nART included older patient age, history of diabetes, taller height, and protease inhibitor use. Conclusion Signs of peripheral neuropathy remain despite virologic/immunologic control but frequently occurs without symptoms. Aging is a risk factor for peripheral neuropathy/SPN.

show abstract

“…However, a survey among HIV-infected patients in six international sites found HCV seropositivity was not associated with increased SN risk [67]. …”

Section: Other Complications Of Hiv/hcv Co-infectionmentioning

confidence: 99%

HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies

2011

View full text Add to dashboard Cite

World-wide, hepatitis C virus (HCV) accounts for approximately 130 million chronic infections, with an overall 3% prevalence. Four to 5 million persons are co-infected with HIV. It is well established that HIV has a negative impact on the natural history of HCV, including a higher rate of viral persistence, increased viral load, and more rapid progression to fibrosis, end-stage liver disease, and death. Whether HCV has a negative impact on HIV disease progression continues to be debated. However, following the introduction of effective combination antiretroviral therapy, the survival of coinfected individuals has significantly improved and HCV-associated diseases have emerged as the most important co-morbidities. In this review, we summarize the newest studies regarding the pathogenesis of HIV/HCV coinfection, including effects of coinfection on HIV disease progression, HCV-associated liver disease, the immune system, kidney and cardiovascular disease, and neurologic status; and effectiveness of current anti-HIV and HCV therapies and proposed new treatment strategies.

show abstract

Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV

Abstract: Background: Sensory neuropathy (SN) is common in patients with HIV. Hepatitis C (HCV) coinfec-

Cited by 19 publications

References 27 publications

Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS

Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS

Peripheral neuropathy in HIV: prevalence and risk factors

HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies

Contact Info

Product

Resources

About